Table 1.
Experimental conditions for immunohistochemistry of breast mucinous carcinoma.
| Primary Antibody | Primary Ab (Clone Name) |
Dilution | Antigen Retrieval Method | Intracellular Localization | Positive Thresholds | Supplier |
|---|---|---|---|---|---|---|
| GCDFP-15 | M (D6) | 1:700 | None | Cp | AS ≥ 4 | SIGNET |
| CGA | P | RtoU | None | Cp | AS ≥ 3 | Nichirei |
| SYP | M (27G12) | RtoU | None | Cp | AS ≥ 4 | Nichirei |
| CD56 | M (MRQ-42) | RtoU | 40 min, pH 9 | Cm | AS ≥ 3 | Nichirei |
| AR | M (AR27) | 1:25 | 40 min, pH 9 | N | AS ≥ 3 | Novocastra |
| ER | M (SPI) | RtoU | 40 min, pH 9 | N | AS ≥ 3 | Nichirei |
| PgR | M (A9621A) | RtoU | 40 min, pH 9 | N | AS ≥ 3 | Nichirei |
| HER2 | M (SV2-61γ) | Kit | None | Cm | HS ≥ 3+ | Nichirei |
| Ki-67 | M (MIB-1) | 1:200 | 40 min, pH 6 | N | LI ≥ 5% | Dako |
AR: androgen receptor; CGA: chromogranin A; ER: estrogen receptor; GCDFP-15: gross cystic disease fluid protein-15; HER2: human epidermal growth receptor 2; PgR: progesterone receptor; SYP: synaptophysin; Ab, antibody; M, monoclonal; P, polyclonal; RtoU, ready to use; Cp, cytoplasm; Cm, cell membrane; N, nucleus; AS, Allred score (total score); HS, HER2 score; LI, labeling index; SIGNET, SIGNET Lab, Inc., Dedham, USA; Nichirei, Nichirei Biosciences Inc., Tokyo, Japan; Novocastra, Novocastra Lab, Ltd., Sheffield UK; Dako Japan Inc., Tokyo, Japan.